PriceTargets.com logo

Shield Therapeutics - STX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 2.86 As of 12/4/2024 12:49 PM ET
▲ +0.005 (0.18%)

This chart shows the closing price for STX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shield Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STX

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Shield Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 2.86.

This chart shows the closing price for STX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Shield Therapeutics. This rating has held steady since February 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/9/2023Peel HuntReiterated RatingBuy
6/24/2021Peel HuntReiterated RatingBuy
6/24/2021Peel HuntReiterated RatingBuy
5/18/2021Peel HuntReiterated RatingBuy
5/18/2021Peel HuntReiterated RatingBuy
7/16/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/21/2020Peel HuntReiterated RatingBuy
5/21/2020FinnCapReiterated RatingCorporate
5/1/2020Peel HuntReiterated RatingBuy
5/1/2020FinnCapReiterated RatingCorporate
4/22/2020Peel HuntReiterated RatingBuy
4/22/2020FinnCapReiterated RatingCorporate
4/7/2020Peel HuntReiterated RatingBuy
3/17/2020Peel HuntReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/27/2020FinnCapReiterated RatingCorporate
1/8/2020Peel HuntReiterated RatingBuyGBX 200
1/8/2020Peel HuntReiterated RatingBuyGBX 200
12/5/2019Peel HuntReiterated RatingBuy
(Data available from 12/4/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Shield Therapeutics logo
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More

Today's Range

Now: GBX 2.86
Low: 2.80
High: 2.90

50 Day Range

MA: GBX 3.55
Low: 2.60
High: 4.92

52 Week Range

Now: GBX 2.86
Low: 1.06
High: 7.80

Volume

833,012 shs

Average Volume

4,563,304 shs

Market Capitalization

£22.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Shield Therapeutics?

The following sell-side analysts have issued reports on Shield Therapeutics in the last twelve months:
View the latest analyst ratings for STX.

What is the current price target for Shield Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Shield Therapeutics in the last year. has the lowest price target set, forecasting a price of £100,000 for Shield Therapeutics in the next year.
View the latest price targets for STX.

What is the current consensus analyst rating for Shield Therapeutics?

Shield Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STX.

What other companies compete with Shield Therapeutics?

Other companies that are similar to Shield Therapeutics include El Oro, Apc Technology Group, DG Innovate, StreaksAI and Ideagen. Learn More about companies similar to Shield Therapeutics.

How do I contact Shield Therapeutics' investor relations team?

Shield Therapeutics' physical mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company's listed phone number is +44-191-5118500. The official website for Shield Therapeutics is www.shieldtherapeutics.com. Learn More about contacing Shield Therapeutics investor relations.